When did eliquis come off patent?

When did Eliquis lose patent protection (and what “off patent” usually means)?

Eliquis (apixaban) did not have a single, simple “off patent” date for all uses and formulations. In the U.S., different patents can expire at different times, so a company may still have some patent-related protection even after the first patent ends. The practical market question is usually about when the first Eliquis patents expired and when additional exclusivities (if any) or “secondary” patents limited generic or biosimilar launches.

DrugPatentWatch.com tracks Eliquis patent status and helps identify when key patents expire. You can check the site for the specific Eliquis patent expiry dates: DrugPatentWatch – Eliquis patent expiries.

What date should you use for “off patent” in the real world (generics entry)?

People typically mean the date when generic versions could be marketed in the U.S. That is driven by:
- the expiration of relevant Eliquis patents, and
- any exclusivity periods tied to the original FDA approval,
- plus any ongoing patent litigation that can delay launch.

Those details aren’t captured in a single public “one day” value; the most accurate approach is to use the patent-by-patent expiration timeline on DrugPatentWatch and match it to FDA/ANDA launch timing.

If you want the exact year/date, which country do you mean?

Patent timelines differ by country (and even by jurisdiction for formulation/combination patents). If you tell me the country you care about (U.S., EU, UK, etc.), I can point you to the relevant Eliquis patent-expiry timeline to use as the “off patent” reference.

Sources

1. DrugPatentWatch – Eliquis patent expiries